Actionable news
0
All posts from Actionable news
Actionable news in QURE: UNIQURE N.V.,

uniQure Expands Intellectual Property Portfolio with Newly Issued Patent Providing Broad Protection of Insect Cell-Based AAV Manufacturing

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, July 18, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (QURE), a leader in human gene therapy and AAV manufacturing, today announced that the United States Patent and Trademark Office (USPTO) has granted a patent for a proprietary invention by uniQure which broadly covers an important component of insect cell-based AAV manufacturing technology. The USPTO issued patent number US 9,708,627, a member of one of uniQure’s Hermens patent families, with claims covering the expression of both Rep78 and Rep52 proteins from a Rep78 nucleic acid sequence in insect cells.

The newly issued Hermens ‘627 patent significantly expands uniQure’s leading intellectual property portfolio related to large-scale, highly reproducible manufacturing of AAV in insect cells. This patent, which broadens earlier claims granted in this patent family, is based on years of research by uniQure scientists focused on enhancing the genetic stability of the Rep78/52 encoding sequences used to produce AAV vectors in insect cells. The technology covered in the Hermens ‘627 patent family is currently widely applied in insect cell-based AAV manufacturing.

“As an early pioneer of insect cell-based AAV manufacturing, we have continued to innovate and protect all aspects of our proprietary technology that are essential for the efficient and large-scale production of AAV vectors for commercial use,” stated Jonathan Garen, chief business officer for uniQure. “With the issuance of this patent, we have significantly increased the value of our patent portfolio and advanced our leadership in the manufacturing of AAV-based gene therapies.”

uniQure’s...


More